BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3271285)

  • 1. [Subcutaneous administration of deferoxamine in a patient with panmyelopathy and post-transfusion hemosiderosis].
    Zdziarska B; Urasiński I
    Pol Arch Med Wewn; 1987 Jul; 78(1):48-51. PubMed ID: 3271285
    [No Abstract]   [Full Text] [Related]  

  • 2. [The effect of desferrioxamine on the treatment of transfusion hemosiderosis--with special reference to the method of its administration (authors' transl)].
    Fujiyama N; Nakazawa K
    Rinsho Ketsueki; 1977 Dec; 18(12):1393-400. PubMed ID: 604522
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis.
    Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
    Trans Assoc Am Physicians; 1977; 90():335-41. PubMed ID: 611665
    [No Abstract]   [Full Text] [Related]  

  • 4. [Current status of treatments with desferrioxamine B in post-transfusion hypersiderosis in children].
    Orsini A; Raybaud C; Bernard PJ; Aquaron R; Passeron P
    Mars Med; 1967; 104(4):331-7. PubMed ID: 5621537
    [No Abstract]   [Full Text] [Related]  

  • 5. Continuous high-dose intravenous desferrioxamine treatment for iron overload.
    Sidi Y; Shaklai M; Liban E; Pinkhas J
    Isr J Med Sci; 1981 May; 17(5):348-51. PubMed ID: 7263191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Continuous subcutaneous desferrioxamine infusions in patients with hemosiderosis (author's transl)].
    Tillmann W; König R; Schröder K; Schröter W
    Monatsschr Kinderheilkd; 1982 Mar; 130(3):171-2. PubMed ID: 7087975
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of continuous subcutaneous infusion of deferoxamine in a boy with congenital hypoplastic anemia].
    Ishitoya N; Gomibuchi I; Fujisawa K; Akatsuka J
    Rinsho Ketsueki; 1988 Sep; 29(9):1408-12. PubMed ID: 3216512
    [No Abstract]   [Full Text] [Related]  

  • 8. Congenital erythroblastic hypoplasia. Treatment of transfusion hemosiderosis with desferrioxamine B.
    Hildner FJ; Monto RW; Rebuck JW
    Henry Ford Hosp Med J; 1968; 16(2):147-55. PubMed ID: 5650037
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapy of hemosiderosis with deferoxamine].
    Strohmeyer G; Stremmel W
    Dtsch Med Wochenschr; 1984 Nov; 109(44):1669-70. PubMed ID: 6489179
    [No Abstract]   [Full Text] [Related]  

  • 10. [Long-term study in congenital refractory anemia and secondary siderosis].
    Tuschy U; Schmidt U; Meinhold J; Wutke K
    Z Gesamte Inn Med; 1982 Apr; 37(7):213-7. PubMed ID: 7102009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 12. [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
    Krüger N; Kijewski H; König R; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1984 Nov; 109(44):1682-5. PubMed ID: 6489181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR; Mahony BS; Githens JH; Rhoades ED
    Am J Pediatr Hematol Oncol; 1982; 4(2):115-23. PubMed ID: 7114394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desferal therapy in iron storage disease.
    Thompson RB; Owen DM; Bell WN
    Am J Med Sci; 1967 Apr; 253(4):453-60. PubMed ID: 6021380
    [No Abstract]   [Full Text] [Related]  

  • 15. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.
    Silliman CC; Peterson VM; Mellman DL; Dixon DJ; Hambidge KM; Lane PA
    J Lab Clin Med; 1993 Jul; 122(1):48-54. PubMed ID: 8320490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis.
    Smeets ME; Vreugdenhil G; Holdrinet RS
    Am J Hematol; 1996 Mar; 51(3):243-4. PubMed ID: 8619408
    [No Abstract]   [Full Text] [Related]  

  • 17. Iron overload in cardiac valvular disease and pure red cell aplasia: treatment with desferrioxamine.
    Hehlmann R; Schmitz H; Krüger K
    Int J Cardiol; 1984 Jun; 5(6):749-53. PubMed ID: 6235195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Continuous subcutaneous deferoxamine treatment in thalassemia major. Decrease of hemosiderosis and improvement of liver function].
    Krüger N; Ullrich D; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1985 Nov; 110(48):1848-51. PubMed ID: 4064938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusion hemosiderosis. Report of a case treated with desferrioxamine-B.
    Kaung DT
    J Iowa Med Soc; 1965 Jun; 55(6):312-6. PubMed ID: 5835475
    [No Abstract]   [Full Text] [Related]  

  • 20. Vitamin C and iron.
    Nienhuis AW
    N Engl J Med; 1981 Jan; 304(3):170-1. PubMed ID: 7442737
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.